Black Diamond Therapeutics: Targeted Approach And Early Efficacy Signals Create Potential For Significant Upside

When I covered Black Diamond Therapeutics (NASDAQ: BDTX ) earlier this year , I did not find their decline justified by the facts, particularly in light of upcoming trial readouts in an areaI have my PhD in biochemistry and have worked for years analyzing clinical trials and biotech companies. It is my passion to educate everyone possible on the science behind the businesses that we invest in, and it's my mission to help you do your due diligence and not get burned by the pitfalls of investing in this space ...